The researchers, who made the discovery in working with mouse cells, say this is the first time a tumor-suppressor protein has been found to have such a dramatic dual role. But there may be a silver lining in menin's dark side - understanding the mechanism could open up new avenues of treatment for the very leukemias that menin promotes.
Normally menin binds with another protein, known as MLL, in the nucleus of a cell, where the two are part of a complex of proteins that promote proper cell growth. But when MLL is mutated, it becomes a cancer-promoting oncoprotein. Usually this would put the tumor suppressor and the oncoprotein in direct conflict, as each sought to overwhelm the other, but not so in cases of acute leukemia. "We've discovered a situation where they're not antagonizing each other's actions, they're actually working together," said Michael Cleary, MD, professor of pathology and of pediatrics and senior author of the paper published in the Oct. 21 issue of Cell.
When the blood system is functioning properly, the menin and the normal MLL proteins work together constructively, helping guide cells through all the stages of development from their beginnings as blood-forming stem cells to final maturation, or differentiation, into blood cells. But when MLL is mutated, the differentiation process stalls at an intermediate stage and the immature cells begin proliferating uncontrollably.
Given that menin is highly effective in suppressing endocrine tumors, Cleary and first author Akihiko Yokoyama, a postdoctoral scholar in pathology, suspected that MLL was somehow deactivating menin's suppressive powers. They tested the theory with mouse cells in vitro by introducing the mutated MLL oncoprotein and letting leukemia begin to thrive. Yokoyama then genetically removed menin from the cancer cells.
If menin and MLL were struggling against each other, the researchers reasoned that removing menin would either have no effect on the rate of proliferation, or the leukemia would run even wilder, flourishing without restraint. But the leukemia ground to a halt.
"The cells actually stopped proliferating," said Yokoyama, adding, "If you had to predict the outcome, you would've predicted exactly the opposite of what occurred."
Even more unexpected was what happened next - the former cancer cells matured. Like juvenile delinquents steered away from a life of crime when a bad influence is removed, the immature blood cells not only ceased their bad behavior once the menin was gone, they resumed productive lives. They completed the differentiation process and became mature blood cells. The leukemia disappeared without a single cancer cell being killed.
Further work by Yokoyama established that menin was actively involved in promoting the acute leukemia, rather than simply being passive raw material for MLL to use. "This is the first example that we know of where an oncoprotein and a tumor-suppressor protein are physically working together to promote cancer," said Cleary.
Exactly what causes menin to behave as it does in acute leukemia isn't clear. What at first appears to be Jekyll-and-Hyde behavior may simply be a matter of slavish devotion to its mission, with the protein plying the only trade it knows regardless of whether its actions inhibit cancer or, in the case of acute leukemia, promote it.
Not knowing just how menin does what it does, the researchers said it's difficult to speculate whether similar processes could be happening elsewhere in the human body. But the findings offer tantalizing possibilities for pursuing new treatments for MLL-associated acute leukemias, which make up between 5 and 10 percent of all leukemias in both adults and children. Acute leukemias associated with MLL oncoproteins are extremely aggressive and patients generally don't respond well to conventional treatments.
But the stunning reversal of leukemia in the mouse cells when menin was removed offers clues for developing treatments. If the team's findings can be applied to humans, "we would probably stop a leukemia dead in its tracks," said Cleary. There's a lot more that needs to be learned before that could be attempted, but Yokomama and Cleary are cautiously optimistic.
"We're chipping away at the molecular mechanism for how the MLL oncoprotein works," said Cleary. "The more basic knowledge we have, the more chance we have of designing more effective and specific treatments."
Other Stanford researchers involved in the study are Tim Somervaille, MD, PhD, postdoctoral scholar in pathology, and Kevin Smith, PhD, basic life science research associate in pathology.
The project was funded by the National Cancer Institute and the Lucile Packard Foundation for Children's Health.
Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.
PRINT MEDIA CONTACT: Louis Bergeron at (650) 723-3900 (louisb3@stanford.edu)
BROADCAST MEDIA CONTACT: M.A. Malone at (650) 723-6912 (mamalone@stanford.edu)
Journal
Cell